AstraZeneca Pharma India Limited — Financials & Forensics
NSE: ASTRAZEN · BSE: 506820 · ISIN: INE203A01020
18 Aug 2026
Add ASTRAZEN to your watchlist — all of this, automated.
Sign in with GoogleAnnual P&L snapshot
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue from operations | ₹806 Cr | ₹1,003 Cr | ₹1,296 Cr | ₹1,716 Cr | ₹2,276 Cr |
| EBITDA | ₹86 Cr | ₹165 Cr | ₹184 Cr | ₹254 Cr | ₹262 Cr |
| EBITDA margin | 10.7% | 16.5% | 14.2% | 14.8% | 11.5% |
| Profit after tax | ₹62 Cr | ₹99 Cr | ₹162 Cr | ₹116 Cr | ₹188 Cr |
Deeper analysis
Recent filings by AstraZeneca Pharma India Limited
-
Press Release
11 Aug 2026 · Financial Results
-
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
10 Aug 2026 · General Update
-
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
10 Aug 2026 · Financial Results
Never miss a filing again
About AstraZeneca Pharma India Limited on Indian Stock Alerts
Indian Stock Alerts tracks AstraZeneca Pharma India Limited's SEBI / exchange filings in real time. Every quarterly result, audited annual report, shareholding pattern update, insider trade and corporate announcement is automatically parsed and surfaced as a structured data point — with a link back to the underlying filing.
Data points refreshed daily include closing price, 1Y change, market cap, P/E, ROE, dividend yield, RPT volume, audit / governance / accrual flags. Quarterly results numbers refresh within minutes of the company filing them with BSE / NSE.